Anavex Life Sciences Corp. Stock News

During the last session, Anavex Life Sciences Corp. (NASDAQ:AVXL)s traded shares were 3.16 million, with the beta value of the company hitting 0.61. At the end of the trading day, the stocks price was $18.14, reflecting an intraday gain of 1.23% or $0.22. The 52-week high for the AVXL share is $31.50, that puts it Anavex Life Sciences Corp. (NASDAQ: AVXL) Fall -27.93% In Six Months, Heres What We Should Expect Now Read More »

Anavex Life Sciences Corp. (NASDAQ:AVXL) has received an average recommendation of Buy from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokerages that []

Opus Capital Group LLC grew its position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 57.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,500 shares of the biotechnology company’s stock after buying an additional 6,000 shares during the quarter. […]

Thursday, January 13, 2022 at 8:15 am Pacific Time / 11:15 am Eastern Time Thursday, January 13, 2022 at 8:15 am Pacific Time / 11:15 am Eastern Time

Royal Bank of Canada lifted its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 23.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,488 shares of the biotechnology companys stock after buying an additional 2,346 shares during the period. Royal Bank []

Absci (NASDAQ:ABSI) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk. Analyst Ratings This is a summary of current recommendations and price targets for Absci and []

Stem cell therapies are back in vogue, at least for this Miami-based biotechnology company.

Morgan Stanley increased its position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 218.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 271,673 shares of the biotechnology companys stock after purchasing an additional 186,329 shares during the quarter. Morgan Stanley owned []

AVXL earnings call for the period ending September 30, 2021.

Anavex Life Sciences Corp. (NASDAQ:AVXL) has a beta value of 0.61 and has seen 2.19 million shares traded in the last trading session. The company, currently valued at $1.46B, closed the last trade at $19.40 per share which meant it lost -$1.04 on the day or -5.09% during that session. The AVXL stock price is Anavex Life Sciences Corp. (AVXL): Why Is The Stock Strong? Read More »

NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap

NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, is scheduled to participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 2, 2021 at 12:10 p.m. ET.

NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeu

BTIG Research reaffirmed their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research note issued to investors on Thursday morning, Price Targets.com reports. BTIG Research currently has a $34.00 price objective on the biotechnology companys stock. AVXL has been the subject of several other reports. Zacks Investment Research upgraded Anavex Life Sciences []

Goldman Sachs Group Inc. cut its position in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 33.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 90,117 shares of the biotechnology companys stock after selling 45,755 shares during the period. Goldman Sachs Group Inc. owned about 0.13% []